ASO Author Reflections: The Role of Neoadjuvant Chemotherapy Among Elderly Patients with Locally Advanced Gastric Cancer

Excerpt

In the United States, approximately one-half of patients with newly diagnosed gastric cancer (GC) are aged 75 years or older.¹ As the population ages, the number of elderly patients undergoing gastrectomy for GC will continue to increase.² Advances in multimodal treatment have improved outcomes of patients with GC. Whether receipt of perioperative chemotherapy confers the same survival benefit among elderly patients undergoing resection has not been well studied. While noncompliance with perioperative chemotherapy might negatively affect outcomes, adverse events after neoadjuvant chemotherapy (NAC) may decrease the ability to perform definitive surgery among elderly patients with GC.³ Therefore, the current study defined the impact of NAC on outcomes among elderly patients with locally advanced GC undergoing gastrectomy.⁴ …